Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Calico
Biotech
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests
Neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed ALS progression, causing misses on the primary endpoints.
Nick Paul Taylor
Jan 7, 2025 5:52am
Terray assembles $120M series B to advance AI-powered molecules
Oct 17, 2024 10:37am
John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders
Mar 29, 2024 9:30am
AbbVie and Calico drug boosts immunotherapy response in mice
Oct 5, 2023 11:19am
AbbVie hits go on $1B re-upped Calico deal
Jul 27, 2021 10:13am
Pfizer hires Settleman from Calico to lead cancer R&D
Jun 6, 2019 8:33am